Comment from National Organization for Rare Disorders (NORD)

Summary: The National Organization for Rare Disorders (NORD) supports the Haystack Project's petition to improve the FDA's review process for rare diseases. They argue for the use of clinically meaningful endpoints from natural history studies, the consideration of alternative trial designs to randomized controlled trials, and the inclusion of patient and caregiver expertise in the regulatory process.